Drugs / QH101
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07656103 | May 2026 → May 2027 expected | malignant tumor of meninges, metastatic malignant neoplasm in the brain, metastatic malignant neoplasm in the spinal cord | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07131085 | Aug 2025 → Dec 2027 expected | acute myeloid leukemia, myelodysplastic syndrome | Anhui Provincial Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07307053 | Jan 2026 → Jan 2029 expected | high grade malignant neoplasm, metastatic neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QH101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07307053 ↗ |
| Action | Deplete | “significantly improving tumor cell elimination efficiency” NCT07131085 ↗ |
| Modality | Cell therapy | “QH101 is an allogeneic TCR-enhanced Vδ2 T cell therapy product” NCT07131085 ↗ |
| Route | Intrathecal | “via intrathecal infusion” NCT07307053 ↗ |